English
Back
Download
Log in to access Online Inquiry
Back to the Top

AbbVie upgraded to buy at Societe Generale; sees 48% upside

Societe Generale has upgraded $AbbVie (ABBV.US)$ to buy from hold on what it views as better than expected execution of its immuno-inflammation and aesthetics businesses.
The firm also raised its priced target from $111 to $172 (~48% upside).
Analyst Justin Smith said that AbbVie has taken over from Bristol-Myers Squibb (BMY +1.4%) as his preferred value call in the global large cap pharma space.
Following AbbVie's Q3 earnings results, Smith has "full conviction" in the company's long-term guidance for the Allergan aesthetics franchise.
AbbVie upgraded to buy at Societe Generale; sees 48% upside
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
3
19
+0
10
Translate
Report
24K Views
Comment
Sign in to post a comment
417
Followers
3
Following
521
Visitors
Follow
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.